Free public records show Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. in 1 of the markets we cover. It is not a key player in our research.
[1] ClinicalTrials.gov, Studies led by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.
From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.
2 active studies led by Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., of 2 in all
Source: ClinicalTrials.gov, Studies with Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.
Markets we cover where free public records show Zhejiang Hanmai Pharmaceutical Technology Co., Ltd.: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.
The topics of the markets Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. is in.
Stories on the topics Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. works in.
About 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Read
57 million people live with dementia. In May 2025 the US FDA cleared the first blood test used to help…
Read
The FDA has approved one cannabis-derived medicine, Epidiolex, for rare epilepsies, and three synthetic…
ReadSearch all reports for Zhejiang Hanmai Pharmaceutical Technology Co., Ltd. All companies